In many ways, studies on inflammatory cytokines follow the same spectrum of experiments as did studies on bacterial products, particularly the lipopolysaccharide (LPS) of Gram-negative bacteria and the exotoxins of Gram-positive bacteria. Either Staphylococcal exotoxins or endotoxins were known to cause fever, inflammation, tissue destruction and, in the case of systemic administration, shock and death. An almost identical portfolio of activities exists for either TNF or interleukin-1 (IL-1); that is, these cytokines mimic the toxicity of host responses to bacterial products and hence blocking TNF or IL-1 prevents death from bacteremia. 1,2 Although IL-1 and TNF are involved in the pathogenesis of non-infectious diseases, the mechanisms for IL-1 and TNF being pro-inflammatory cytokines are shown in Figure 1 . Fig. 1. IL-1 and TNF as pro-inflammatory cytokines.
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There is little question that the major advance in treating patients with septic shock was the availability of broad spectrum antibiotics. The field entered a new era when it was shown that neutralizing antibodies to the inflammatory cytokine tumor necrosis factor (TNF) prevented death in mice, rabbits, or baboons, given a lethal injection of Escherichia coli or endotoxin. Similar results were observed with high doses of IL-1 in animals. Injecting a combination of low doses of IL-1 plus TNF revealed that these two cytokines acted synergistically in inducing a shock-like state. For the patient without overt infection, for example multiple trauma, the preclinical data demonstrated that the systemic injection of either IL-1 or TNF into experimental animals induced physiological, hematological and pathological changes which were nearly identical to those observed during bacteremia or multiple trauma. Therefore, there was no lack of data that supported the concept that blocking IL-1 and/or TNF would reduce mortality in patients with septic shock or systemic inflammation. Although the clinical trials in septic patients have not resulted in any approved anti-IL-1 or anti-TNF products, the concept continues to have broad support based on the biology of these cytokines.
In contrast, therapeutic benefit of these same bacterial products in animal models has been characterized by the induction of a state of resistance 3 called 'non-specific host defense'. Non-specific host defense means just that. It has been shown using models of death from infection, growth of tumors, allergen hypersensitivity, hyperoxic lung damage, inflammatory bowel disease, immune-mediated arthritis, radiation and cerebral malaria. The usual model is one in which a bacterial product is administered several hours before a lethal or inflammatory event. Animals treated with a low dose of LPS 12-24 h before are protected against the same LPS given in lethal doses and also against non-LPS challenges.
What has this to do with blocking cytokines for therapy? When recombinant cytokines became available, many investigators repeated the 'non-specific host defense' experiment replacing a priming dose of LPS with TNF or IL-1. It became clear that small doses of these inflammatory cytokines downregulated the responses to a wide spectrum of noxious challenges by a variety of mechanisms. These include a reduction in IL-1 and TNF surface receptors, 4 upregulation of soluble receptors and receptor antagonists, increased production of anti-inflammatory cytokines and increased synthesis of heat shock proteins and other mechanisms of intracellular protection. It was concluded that the mechanism for LPSinduced protection was the ability of LPS to stimulate the synthesis of these cytokines which, in turn, afforded the protection by several mechanisms listed above.
The next step was to administer the cytokines to patients for protection against radiation and chemotherapy. But investigators were not surprised that IL-1 and TNF were as toxic as bacterial products (reviewed by Dinarello 5 ). Attention focused on the concept that the biological property of IL-1 and TNF needed to be blocked. For TNF, IL-1 and several chemokines, in vitro, animal and human data support this concept. Clinical data show that neutralization of TNF activity 6 or IL-1 receptor blockade [7] [8] [9] are beneficial in rheumatoid arthritis, inflammatory bowel disease 10 or graft versus host disease. 11 In the case for anti-cytokine therapy for sepsis, the results have been disappointing. In the past 5 years, the 28 day mortality in patients with sepsis syndrome has decreased somewhat but still ranges from 30 to 50%; mortality in those with septic shock and multiple organ failure is higher despite aggressive intensive care. Intensive care units deliver hemodynamic, metabolic, ventilatory and renal support and critical care has become a recognized medical subspecialty. Clearly some patients survive the ordeal but it remains frustrating for the intensivist who cannot halt and reverse the downhill course leading to multiple organ failure and death. Ideally, anti-cytokine therapy should be able to 'rescue' the patient who continues to deteriorate in the face of considerable support efforts. Unfortunately, there is still no therapeutic agent or combination of treatments which have significantly reduced the mortality of this disease over that achieved with up-to-date intensive care strategies.
Although specific and successful monotherapy for a particular disease is a desirable goal in therapeutics, there are increasing examples where treatment is most effective when two or more agents are used. The obvious examples are cancer, autoimmune diseases and HIV-1 where treatment with a single anti-tumor drug or immunosuppressive regimen or anti-viral agent has been replaced with use of several agents each targeting a somewhat different mechanism. If more than one agent would benefit the patient with septic shock, there are several possible combinations. In sepsis involving a Gram-negative organism, endotoxin itself acts like a cytokine in that it activates nearly the same genes as does IL-1 and TNFα. A combination of neutralizing antibodies to endotoxin as well as blocking TNF and/or IL-1 may offer the patient with Gram-negative septic shock the greatest chance of rescue. Administration of anti-IL-8 with either anti-TNF or anti-IL-1 may be effective for patients with a high risk of developing ARDS. The concept of combining more than one anti-cytokine agent has sound experimental basis. For example, in animals, a combination of anti-TNF plus anti-IL-1 treatment has increased survival over that using either agent as monotherapy.
Is the failure to rescue patients with anti-TNF or IL-1 blockade due to a delay in intervention? In many patients (75%) with sepsis syndrome, blood pressure and organ perfusion are unimpaired; however, when septic shock develops, circulatory collapse within a few hours is thought to coincide with the onset of a new bacteremia or endotoxemia. In addition, a 'cytokine storm' is thought to be responsible for triggering the shock. It has been the wisdom of anti-cytokine therapy that these patients also stand the greatest chance of a 'rescue' by blocking further cytokine receptor triggering. In other patients with similarly serious infections, a fall in blood pressure or the development of organ failure is slower (over days) and cytokine receptors may have already been engaged before circulatory collapse reaches the level of entry criteria into a trial. In those patients, the administration of anti-cytokine therapy may be too late to provide a successful rescue. Whereas animal studies have provided a compelling argument that blocking TNF or IL-1 would be a therapeutic success in treating septic shock, in animals the window of time for reversing the events of lethal sepsis is rather small. Does that mean that by the time the patient has overt signs of septic shock that it is too late for rescue with anti-cytokine therapy?
In most of the anti-cytokine trials, the time that passes before a patient actually receives therapy can be 12-24 h after the early indications of altered mental status or blood pressure instability. This 'delay' in administering anti-cytokine therapy is best shown for IL-1Ra. As shown in Figure 2 , because only a few receptors need to be occupied by bona fide IL-1β, IL-1 activity can take place when only a few receptors are unoccupied (upper drawing). As shown in the lower drawing, IL-1Ra occupancy of all available IL-1R results in no IL-1 biological activity. Therefore, if the infusion of IL-1Ra is delayed, the upper drawing condition may exist and little therapeutic effect will occur. What can be done to shorten the time between overt evidence of a life threatening process and initiation of anti-cytokine therapy?
Despite the fear that blocking IL-1 and TNF in humans with inflammatory diseases or sepsis would endanger their natural host defenses, to date, there have been no consistent findings that patients receiving these anti-cytokine agents are at risk. This observation is in light of the fact that the population is at higher risk for infection compared to the healthy population. A metaanalysis of all the anti-inflammatory and anti-cytokine therapies in septic patients concluded that the consistent survival benefit in these patients, although not reaching significance for regulatory approval, did indicate that anti-IL-1-and anti-TNF-based therapies are safe. 12 What is the future of anti-cytokine therapy? For patients with local inflammatory diseases of joints, serosa, skin, bowel, heart and liver, for example, blocking IL-1 or TNF appear appropriate in that some clinical studies have already shown efficacy. More will come. However, for the patient in septic shock, the trials are less than optimal because of the patient heterogeneity and the late entry into the trials. It may be best to carry out small trials of highly selected patients undergoing 'cytokine storm' to rescue from the downhill course of septic shock. Fig. 2 . IL-1Ra competes with IL-1β for triggering of IL-1 receptors. Upper drawing, only a few receptors need to be occupied for IL-1 activity to take place. Lower drawing, IL-1Ra occupancy of all available IL-1R results in no IL-1 biological activity.
